Diazepam 10 mg

1. Classification and Chemical Overview

Diazepam (historically marketed under the brand name Valium) is a core long-acting 1,4-benzodiazepine derivative possessing anxiolytic, sedative, anticonvulsant, muscle-relaxant, and central amnesic properties. Under the Anatomical Therapeutic Chemical (ATC) classification system, it is indexed under N05BA01.

Chemically designated as 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one, diazepam features a classical 1,4-benzodiazepine ring with a chlorine substituent at position 7 and a methyl group at position 1. In United Kingdom and European clinical practice, the 10 mg dose is presented as oral tablets (typically scored and color-coded blue). Under the Human Medicines Regulations 2012, diazepam is classified as a Prescription Only Medicine (POM) and is controlled under Schedule 4 (Part IV) of the Misuse of Drugs Regulations 2001 (as amended).

2. Mechanism of Action and Pharmacodynamics

Diazepam operates as a potent, high-affinity positive allosteric modulator at central nervous system VOORKANTA​ receptor complexes. It binds to the specific benzodiazepine site at the interface between the $\alpha$ en γ2​ subunits of the ionotropic VOORKANTA​ receptor.

Binding facilitates an increase in the frequency of GABA-induced channel opening, enhancing chloride ion conductance into the postsynaptic neuron. The subsequent hyperpolarisation stabilizes the neuronal membrane, dampening action potential generation across the limbic system, cerebral cortex, spinal cord interneurons, and reticular formation.

The 10 mg strength provides substantial central nervous system suppression suitable for severe acute conditions, muscle hypertonicity, or severe motor agitation.

3. Approved UK Clinical Indications and Therapeutic Scope

Licensing for oral diazepam 10 mg includes:

• Severe Anxiety: Short-term management of severe, disabling anxiety or agitation (2 mg to 10 mg taken 2 to 4 times daily).

• Acute Muscle Spasm: Symptomatic relief of acute muscle spasms associated with cerebral palsy, paraplegia, athetosis, or local spinal pathology.

• Acute Alcohol Withdrawal: Mitigation of agitation, tremor, impending delirium tremens, and hallucinosis (10 mg taken 3 to 4 times daily during the first 24 hours, followed by tapering).

• Pre-medication & Sedation: Pre-procedural or pre-operative sedation prior to minor surgical or diagnostic interventions.

Note on 10 mg Dosage Strength: The 10 mg strength represents the higher standard single oral dose for adults. It is generally reserved for severe anxiety states, acute muscle spasms, or acute alcohol detoxification regimes.

NICE & BNF Guidance Context: In accordance with UK guidelines, prescribing for anxiety or insomnia must be restricted to short-term course durations (2 to 4 weeks maximum). Continuous treatment leads to pharmacological tolerance, loss of clinical efficacy, and physical dependence. The 10 mg dose should be avoided as a starting dose in elderly or debilitated patients (where 2 mg is recommended) due to elevated risks of heavy sedation, cognitive impairment, and falls.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Diazepam is rapidly and almost completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations (Tmax​) occur within 30 to 90 minutes. Absolute oral bioavailability exceeds 90%.

• Distribution: Diazepam is highly lipophilic and rapidly crosses the blood-brain barrier. It distributes widely throughout peripheral fat tissue, displaying a large steady-state volume of distribution (Vd​) of $0.8\text{ to }1.0\text{ L/kg}$. Plasma protein binding is very high (98% to 99%), bound primarily to human serum albumin.

• Biotransformation: Diazepam undergoes extensive hepatic Phase I metabolism via Cytochrome P450 enzymes (predominantly CYP2C19 and CYP3A4). It is demethylated to $N$-desmethyldiazepam (nordiazepam; active, t1/2​=30–100 hours), hydroxymidazolam/temazepam, and ultimately oxazepam. These active metabolites undergo Phase II glucuronidation before renal excretion.

• Elimination: Biphasic elimination is observed. The initial rapid distribution phase is followed by a prolonged terminal elimination phase (t1/2​=20–50 hours for parent diazepam; total elimination half-life including nordiazepam can exceed 100 hours). Excretion occurs mainly via the kidneys as glucuronidated metabolites.

5. Physiological Effects and Adverse Event Spectrum

Diazepam depresses neuronal excitability, leading to rapid reduction in anxiety, skeletal muscle relaxation, sedation, anterograde amnesia, and elevation of seizure thresholds.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Drowsiness, fatigue, somnolence, lightheadedness, muscle weakness, ataxia.

• Common ($\ge 1/100$ to $<1/10$): Confusion, depression, dysarthria, slurred speech, headache, tremor, dizziness, constipation, dry mouth, nausea.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Hypersensitivity reactions, changes in libido, gastrointestinal disturbance, memory impairment/anterograde amnesia, urinary retention or incontinence.

• Rare ($\ge 1/10,000$ to $<1/1,000$): Respiratory depression, hypotension, bradycardia, cardiac arrest, jaundice, blood dyscrasias, paradoxical reactions (including acute excitement, agitation, rage, hallucinations, and insomnia).

6. Contraindications, Drug Interactions, and Clinical Precautions

Contra-indicaties

• Hypersensitivity to diazepam or other benzodiazepines.

• Acute severe respiratory insufficiency or respiratory depression.

• Severe sleep apnoea syndrome.

• Myasthenia gravis.

• Severe hepatic impairment (risk of precipitating hepatic encephalopathy).

• Acute narrow-angle glaucoma.

Key Drug Interactions

• CNS Depressants & Alcohol: Concomitant administration with opioids, sedatives, antipsychotics, or alcohol produces marked additive CNS depression, profound respiratory depression, coma, and death.

• CYP2C19 / CYP3A4 Inhibitors: Co-administration with strong inhibitors (e.g., omeprazole, cimetidine, fluvoxamine, ketoconazole, clarithromycin) decreases clearance, raising plasma concentrations and prolonging sedation.

• CYP Inducers: Concomitant use with inducers (e.g., rifampicin, carbamazepine, phenytoin, St John’s Wort) increases clearance, reducing therapeutic effect.

• Opioids: Combined use significantly elevates the risk of fatal overdose; co-prescribing must be restricted strictly to situations where alternative treatments are inadequate.

Clinical Precautions and Monitoring

• Tolerance & Withdrawal: Physical and psychological dependence can develop within weeks. Abrupt withdrawal after prolonged use causes rebound anxiety, tremors, sweating, delirium, and life-threatening withdrawal seizures. Formal gradual dose tapering is required.

• Elderly Patients: Elderly individuals exhibit decreased clearance and increased central sensitivity. A 10 mg dose carries high risks of severe confusion, profound motor ataxia, and traumatic falls.

• Driving and Machinery Operating: Diazepam 10 mg significantly impairs psychomotor performance, reaction time, and alertness. Patients must be warned not to drive or operate heavy machinery while undergoing treatment.